Concepedia

Tamoxifen (Selective Estrogen-Receptor Modulators) and Aromatase Inhibitors as Potential Perioperative Thrombotic Risk Factors in Free Flap Breast Reconstruction

Michael N. Mirzabeigi, Jonas A. Nelson, John P. Fischer, Steven J. Kovach, Joseph M. Serletti, Liza C. Wu, Suhail Kanchwala

Plastic & Reconstructive Surgery · 2015 · 37 citations · 48 references

DOI

Abstract

Tamoxifen may have been previously overestimated as a microvascular thrombotic risk factor. At a minimum, these data suggest that withholding tamoxifen for 2 weeks before surgery can mitigate thrombotic risk.

References

48

Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham et al. · JNCI Journal of the National Cancer Institute · 1998 · 5.5K citations · Full text

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer

Anthony Howell, Jack Cuzick, M Baum et al. · The Lancet · 2005 · 2.3K citations

, , +8

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text

, , +7

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

M Baum, Aman U. Budzar, J Cuzick et al. · The Lancet · 2002 · 2K citations

, , +10

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

Steven R. Cummings, Stephen Eckert, K A Krueger et al. · JAMA · 1999 · 1.9K citations